Selank is a synthetic heptapeptide analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg), with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank is studied for its anxiolytic and nootropic properties in preclinical research models.

Research-grade Selank is used in neuropharmacology laboratories investigating GABAergic modulation, serotonin metabolism, and brain-derived neurotrophic factor (BDNF) expression. Unlike classical benzodiazepines, Selank's mechanism does not involve direct GABA-A receptor binding, making it an interesting subject for anxiety research without the sedation profile of traditional anxiolytics.

Selank has been studied for its effects on memory consolidation, learning, and cognitive performance in rodent models. Research suggests it may modulate enkephalin metabolism and influence the expression of genes involved in the immune response and neuroplasticity.

Research Applications:

• Anxiety and stress response research in preclinical models
• GABAergic and serotonergic neurotransmission studies
• BDNF expression and hippocampal neuroplasticity research
• Cognitive performance and memory consolidation investigations
• Enkephalin metabolism and opioid peptide interaction studies
• Immune modulation and tuftsin receptor research

Key Specifications:

• Purity: 99.856% verified by Freedom Diagnostics testing
• Dosage: 5mg per vial
• Category: Nootropic
• Storage: -20°C or colder (lyophilized)
• Stability: Up to 2 years when stored properly

Research Highlights:

• Synthetic analog of endogenous tuftsin tetrapeptide with extended stability
• Studied for anxiolytic effects without classical benzodiazepine receptor binding
• Research focus on BDNF upregulation and hippocampal neuroplasticity
• Investigated for cognitive enhancement and memory consolidation in rodent models
• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro | Molecular weight: 751.86 Da